# RNDO-564

Source: https://onco.cc/drugs/rndo-564/  
OnCo record `rndo-564` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RNDO-564 is an experimental bispecific antibody from Rondo Therapeutics, in phase 1 trials for urothelial cancer, non-small cell lung cancer and head and neck squamous cell cancer and other cancers.

## Summary

RNDO-564 is a bispecific antibody (T-cell co-stimulatory engager) from Rondo Therapeutics. A CD28 x Nectin-4 bispecific antibody: one arm binds Nectin-4 on tumour cells, the other gives T cells the CD28 co-stimulatory signal. Its furthest stage is phase 1, for urothelial (bladder) cancer, non-small cell lung cancer, head and neck squamous cell cancer and cervical cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/1b alone and with pembrolizumab, enrolling by invitation (NCT07218003). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: RNDO-564
- Modality: Bispecific antibody (T-cell co-stimulatory engager)
- Mechanism: A CD28 x Nectin-4 bispecific antibody: one arm binds Nectin-4 on tumour cells, the other gives T cells the CD28 co-stimulatory signal.

## Sources

- Rondo Therapeutics: rondotx.com: https://www.rondotx.com/
- Rondo Therapeutics: rondotx.com: https://www.rondotx.com/
- Rondo Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07218003
- ClinicalTrials.gov: trials of RNDO-564: https://clinicaltrials.gov/search?intr=RNDO-564

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [CD28](https://onco.cc/targets/cd28/), [Nectin-4](https://onco.cc/targets/nectin4/)
- companies: [Rondo Therapeutics](https://onco.cc/companies/rondo-therapeutics/)
- trials: [RNDO-564 alone or with pembrolizumab](https://onco.cc/trials/nct07218003/)

---
JSON: https://onco.cc/api/v1/entities/rndo-564.json